Sign in
CompletedPhase 3

Interest of S100B Protein for Patient Victim of Minor Traumatic Brain Injury and Treated by Antiplatelet

Key facts

Who runs it
Poitiers University Hospital
Where
France4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
720 people enrolled
Started
25 Jan 2019
Ended
28 Oct 2025
Type of study
Interventional
Treatments tested
  • S100B protein dosing
Record updated
29 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Age > 18 Years old
  • Minor traumatic brain injury measured by a Glasgow score between 13 and 15
  • Antiplatelet agent therapy
  • Free subject without tutorship or curatorship

Who cannot take part

  • Age < 18 years old
  • Traumatic brain injury older than 6 hours
  • Glasgow score <13
  • Patient without any social security system
  • Patient with renforced protection (tutorship, curatorship, …)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

All the patients admitted in emergency department for minor traumatized cranial, with antiplatelet therapy, can be included, after checked inclusion and non inclusions criterias. If they are agree, a blood sample for the dosage of S100b will be done.

Read full original descriptionShow less

No other modification of the medical care, all patients will have tomodensitometria, according with recommendations. The aim of the study is to validate the negative predictive value of S100b in this population.

The group in the trial

  • S100B protein dosingTreatment being tested

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
29 December 2025